Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The therapeutic targets of many of our top startups are also reflected in recent big biopharma acquisitions and partnerships.
Targeting the red hot antibody-drug conjugate market, OnCusp Therapeutics is coming out of the gate with $100 million from investors such as Novo Holdings and OrbiMed.
In a major pivot, Allogene Therapeutics will no longer focus on two of its studies testing blood cancer therapy cema-cel in an effort to extend its financial runway into 2026.
While initial public offering activity was light in 2023, the new year has recorded the first IPO plan—from California-based CG Oncology.
Eli Lilly on Thursday announced the rollout of a new digital healthcare platform to streamline consumer access to its weight-loss drug Zepbound and other medications.
Once dormant due to a lack of commercial success and drug side effects, the radiopharmaceutical space is gaining momentum in the form of increased investment and scientific advances.
With recent scientific advances, milestone approvals and increased dealmaking, the future of treatment for neurological diseases looks brighter—but continued investment, collaboration and patient-focused efforts are key.
Under the deal disclosed Thursday in an SEC filing, bluebird bio doubled the number of covered U.S. patients for its sickle cell gene therapy to a cumulative total of around 200 million people.
The two agreements announced Thursday will allow AbbVie to leverage Umoja Biopharma’s VivoVec delivery platform, which enables patients’ cells to produce their own cancer-fighting CAR-T cells.
The regulator is launching an investigation of Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound and other GLP-1 receptor agonists following patient reports of suicidal ideation, alopecia and aspiration.
In the third deal in as many days, Roche is paying $66 million upfront to MOMA Therapeutics to find new drugs to go after cancer cell growth, with a potential $2 billion total in milestones and royalties.
Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.